The truth is much simpler. Compound interest is one of the easiest concepts to understand once someone explains it clearly. More importantly, it is one of the most important ideas in personal finance, ...

Learn how CDs pay compound interest and how it affects their annual percentage yield (APY) to maximize your savings strategy ...

Share on Pinterest The FDA puts forward a move to exclude GLP-1 drugs from the bulk compounding list. Image credit: VICTOR TORRES/Stocksy On April 30, 2026, the U.S. FDA announced it is considering ...

On April 30, 2026, the U.S. Food and Drug Administration announced that it is proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for ...

The Food and Drug Administration on April 30 proposed excluding Novo Nordisk and Eli Lilly's weight-loss drugs from a key compounding list, potentially limiting large-scale production by outsourcing ...

FDA proposes excluding blockbuster weight-loss drugs from 503B compounding list Move could limit bulk production by outsourcing facilities Novo and Lilly support FDA stance If finalized, the move ...

The FDA has proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, the latest move in a monthslong crackdown on the compounded GLP-1 market. The 503B bulks list ...

The Food and Drug Administration is taking the first step toward potentially allowing compounding pharmacies to produce seven peptides that are currently restricted because of the agency’s previous ...

A mystery drug has shown promise for Parkinson’s disease, improving the mobility and balance of mice with Parkinson’s-like symptoms. The drug works by boosting the brain’s waste disposal system to ...

Weight-loss company Noom has acquired 503A pharmacy Tailor Made Compounding, which Noom said will allow it to expand its behavior change programs and move beyond weight health. Tailor Made provides ...

Eli Lilly stressed that tirzepatide has never been studied in combination with vitamin B12 and warned that the compounders making these products aren’t required to monitor and report potential ...